Fly On the Wall 6/17/13
June 18, 2013
15:14 EDT MNKD MannKind CFO says will consider partnering after examining data
MannKind CFO Matthew Pfeffer said the company has considered waiting to partner until after FDA makes approval determination for AFREZZA, but thinks "optimal" time to partner may be before approval decision is made.
article does not say this.
The Street June 14, 2013
he Street 6/11 By: Adam F
Baker Brothers, already the largest Acadia shareholder, disclosed an upsized 23 percent stake in the company last week. High-conviction stocks in the Baker Brothers portfolio -- think Seattle Genetics (SGEN_) and Pharmacyclics (PCYC_) -- tend to perform really well, sometimes regardless of near-term fundamentals.
Oh yeah, it's worth noting that Acadia has a potential blockbuster drug in pimavanserin, which will be submitted to FDA as a new treatment for Parkinson's disease psychosis near the end of 2014.
The Fly On The Wall June 12, 2013
June 12, 2013
CLDX Celldex price target raised to $19 from $14 at Brean Capital. Brean Capital raised its price target on Celldex due to its strong clinical data and robust pipeline. Shares are Buy rated.
The Scottish Medicines Consortium completed its assessment of Vertex Pharmaceuticals' resubmission for Kalydeco and posted its advice to the SMC website on June 10. Following a resubmission, Kalydeco is not recommended for use within NHS Scotland, the body stated.
do the DD.